These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease. Galati S; Salvadè A; Pace M; Sarasso S; Baracchi F; Bassetti CL; Kaelin-Lang A; Städler C; Stanzione P; Möller JC Neurobiol Aging; 2015 Mar; 36(3):1577-89. PubMed ID: 25596726 [TBL] [Abstract][Full Text] [Related]
25. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia. Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173 [TBL] [Abstract][Full Text] [Related]
26. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Bhidayasiri R; Bronstein JM Med Hypotheses; 2005; 64(5):941-5. PubMed ID: 15780489 [TBL] [Abstract][Full Text] [Related]
28. A novel presentation of an ocular geste antagoniste in cervical dystonia: a case report. Boyd JT; Fries TJ; Nagle KJ; Hamill RW Tremor Other Hyperkinet Mov (N Y); 2013; 3():. PubMed ID: 24386606 [TBL] [Abstract][Full Text] [Related]
29. Levodopa-induced dyskinesia in Parkinson's disease. Brotchie JM; Lee J; Venderova K J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429 [TBL] [Abstract][Full Text] [Related]
30. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790 [TBL] [Abstract][Full Text] [Related]
31. Detection and assessment of the severity of levodopa-induced dyskinesia in patients with Parkinson's disease by neural networks. Keijsers NL; Horstink MW; van Hilten JJ; Hoff JI; Gielen CC Mov Disord; 2000 Nov; 15(6):1104-11. PubMed ID: 11104192 [TBL] [Abstract][Full Text] [Related]
32. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Chung KA; Lobb BM; Nutt JG; McNames J; Horak F Mov Disord; 2010 Apr; 25(5):602-8. PubMed ID: 20213818 [TBL] [Abstract][Full Text] [Related]
33. From Tricks to Treatment-Sensory Input and Dystonic Dyskinesia in Parkinson's Disease. Edwards MJ Mov Disord Clin Pract; 2017; 4(1):6-7. PubMed ID: 30713943 [No Abstract] [Full Text] [Related]
34. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725 [TBL] [Abstract][Full Text] [Related]
35. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565 [TBL] [Abstract][Full Text] [Related]
36. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
37. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186 [TBL] [Abstract][Full Text] [Related]
39. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia. Jeong EH; Sunwoo MK; Song YS Front Neurol; 2018; 9():1133. PubMed ID: 30619078 [No Abstract] [Full Text] [Related]
40. Dyskinesias and the subthalamic nucleus. Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]